August 2024 in “New Zealand Medical Student Journal” The authors highlighted promising developments in JAK inhibitors as targeted treatments for skin diseases such as atopic dermatitis, psoriasis, and alopecia areata, noting their effectiveness and safety profiles. Recent advances also suggest potential for treating melanoma with these inhibitors.
14 citations
,
March 2021 in “Actas Dermo-Sifiliográficas” This review discusses the JAK/STAT signaling pathway's role in immune-mediated skin diseases and examines the efficacy and safety of JAK inhibitors for treating vitiligo and alopecia areata, but reports no new clinical results.
3 citations
,
September 2025 in “Frontiers in Immunology” This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.
1 citations
,
February 2021 in “Farmacja Polska” This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.
17 citations
,
May 2019 in “BMJ Open” This review discusses the potential of drugs targeting the JAK/STAT pathway for dermatological diseases and outlines a protocol to assess existing evidence, reporting no new clinical results.
20 citations
,
December 2020 in “Actas Dermo-Sifiliográficas” This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.